Wang resin

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代醇
• 英文名称: Wang resin
• 英文别名: 2,2,2-Trifluoro-1-(hydroxymethylamino)ethanol
• 化学式: C₈H₉O₂Pol
• 分子量: 145.08
• InChiKey: CQNKDNQZXHXNJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Wang resin 在 溴 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 5.17h， 生成 4-(bromomethyl)phenoxymethylpolystyrene
  参考文献：
  名称：

  WO2007/73095

  摘要：

  公开号：
• 作为产物：
  描述：

  Ditrimethylolpropane tetraisostearate 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 Wang resin
  参考文献：
  名称：

  Traceless solid-phase synthesis of hydroxylated cyclopentenones

  摘要：

  Intramolecular nitrone-alkene cycloadditions on solid phase can be performed using polymer-bound hydroxylamine. Condensation of this reagent with sugar derived 4-pentenals followed by N-O cleavage, quaternization of the amine thus produced, and finally oxidative elimination of the amino group detaches the chiral hydroxylated cyclopentenones from the polymer. The natural antibiotic pentenomycin I was prepared in this way. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.09.080

文献信息

• Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US07138526B1

  公开（公告）日：2006-11-21

  A method for the solid phase synthesis of N,N-disubstituted diazacycloalkylcarboxy derivatives of general formula (I) and (II) is claimed. Examples include piperazine-2-carboxamide. The method is applicable to the synthesis or large combinatorial libraries

  一种用于固相合成一般式（I）和（II）的N,N-二取代二氮杂环烷基羧酸衍生物的方法。示例包括哌嗪-2-羧酰胺。该方法适用于合成大型组合化合物库。
• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030236251A1

  公开（公告）日：2003-12-25

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: 1 wherein R 1 is selected from: H, haloalkyl, (C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-7 )cycloalkyl, (C 2-6 )alkynyl, (C 5-7 )cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 6-10 )bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR 5 , wherein R 5 is H, halogen, haloalkyl, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; X is N or CR 5 ; D is N or CR 5 ; each of Y 1 and Y 2 is independently O or S; Z is O, N, or NR z wherein R z is H, (C 1-6 )alkyl, (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; R 3 and R 4 are each independently H, (C 1-6 )alkyl, first (C 3-7 )cycloalkyl or 6- or 10-membered aryl, Het (C 1-6 )alkyl-6- or 10-membered aryl, (C 1-6 )alkyl-Het; or each R 3 and R 4 are independently covalently bonded together to form second (C 3-7 )cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R 3 or R 4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R 7 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl; or R 7 is covalently bonded to either of R 3 or R 4 to form a heterocycle; A is (C 1-6 ) alkyl-CONHR 8 wherein R 8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.

  公式I所代表的化合物的异构体、对映体、非对映异构体或互变异构体，其中R1选自：H、卤代烷基、(C1-6)烷基、(C2-6)烯基、(C3-7)环烷基、(C2-6)炔基、(C5-7)环烯基、6或10元芳基、Het均可选择性地取代；R2选自(C1-6)烷基、(C3-7)环烷基、(C6-10)双环烷基、6-或10元芳基、或Het均可选择性地取代；B为N或CR5，其中R5为H、卤素、卤代烷基、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；X为N或CR5；D为N或CR5；Y1和Y2中的每一个独立地为O或S；Z为O、N或NRz，其中Rz为H、(C1-6)烷基、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；R3和R4各自独立地为H、(C1-6)烷基、第一(C3-7)环烷基或6-或10元芳基、Het(C1-6)烷基-6-或10元芳基、(C1-6)烷基-Het；或每个R3和R4独立地共价结合在一起形成第二(C3-7)环烷基，或杂环，均可选择性地取代；或当Z为N时，R3或R4中的任一者独立地与之共价结合形成含氮杂环；R7为H、(C1-6烷基)、(C3-7)环烷基或(C1-6)烷基-(C3-7)环烷基；或R7与R3或R4中的任一者共价结合形成杂环；A为(C1-6)烷基-CONHR8，其中R8为6-或10元芳基，或Het；或A为6-或10元芳基，或Het所述芳基或Het可选择性地取代；或其盐或衍生物；这类化合物是HCV NS5B聚合酶的有效抑制剂。
• Substituted piperidine compounds
  申请人：——

  公开号：US20040186135A1

  公开（公告）日：2004-09-23

  Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

  公开了新型的3,4-二取代-4-芳基哌啶化合物。还公开了包含3,4-二取代-4-芳基哌啶化合物的药物组合物及其药物用途的方法。所公开的化合物可用作阿片受体拮抗剂等。
• Fast and effective reduction of nitroarenes by sodium dithionite under PTC conditions: application in solid-phase synthesis
  作者：Robert Kaplánek、Viktor Krchňák

  DOI：10.1016/j.tetlet.2013.03.010

  日期：2013.5

  conditions for the fast and effective reduction of aromatic nitro groups bound to hydrophobic polystyrene-based Wang and Ring resins utilizing sodium dithionite in dichloromethane–water under PTC conditions are reported. Tetrabutylammonium hydrogen sulfate (TBAHS) was found to be an effective phase-transfer catalyst for this reaction. This method allows for the reduction of nitro groups to amino groups under

  在此，报道了在PTC条件下利用连二亚硫酸钠在二氯甲烷-水中快速有效地还原与疏水性聚苯乙烯基Wang和Ring树脂结合的芳族硝基的条件。发现四丁基硫酸氢铵（TBAHS）是该反应的有效相转移催化剂。该方法允许在温和条件下将硝基还原为氨基，并完全转化，并且可以耐受其他官能团。该方法是基于氯化锡（II）的还原方法的优良替代方法，该方法以其缺点而著称。
• Therapeutic uses of tri-aryl acid derivatives
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US07005440B1

  公开（公告）日：2006-02-28

  The use of triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the PPAR receptor.

  使用公式（I）的三芳基酸衍生物及其药物组合物作为PPAR配体受体结合物。本发明的PPAR配体受体结合物可用作PPAR受体的激动剂或拮抗剂。